Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Ltd ADR (NQ: CNTB )

1.508 +0.078 (+5.45%)
Streaming Delayed Price Updated: 1:17 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Connect Biopharma Holdings Ltd ADR

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
Via Newsfile
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Participate in Upcoming September Investor Conferences
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
From Connect Biopharma Holdings Limited
Via Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
From Connect Biopharma Holdings Limited
Via Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
From Connect Biopharma Holdings Limited
Via Business Wire
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
From Connect Biopharma Holdings Limited
Via GlobeNewswire
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.